NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today dosing of the first patient in a phase II trial of ZIO-101 (organic arsenical) for the treatment of patients with primary liver cancer. Primary liver cancer is one of the most commonly occurring cancers in the world. The study will take place at five major U.S. liver cancer treatment centers including sites in New York, Boston, Miami, Seattle, and Atlanta.
